Trial Information

Summary: T-Cell Lymphoma Study CLBH589B2201

Novartis Oncology is conducting a clinical research study to compare the safety and effectiveness of an investigational drug for participants who are 18 years of age and older that have Cutaneous T-cell Lymphoma (CTCL), which is a rare disease where certain cells of the lymph system (T-lymphocytes) become cancerous and affect the skin. An "investigational drug", means that it is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).

Participants will be required to take the investigational drug orally, once a day on Mondays, Wednesdays and Fridays.

For more information about this clinical trial, visit www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: August 28, 2008 at 3:00:19 PM